

Discloser Identifier: 1089528

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Peter Halfmann

Discloser Identifier: 922310

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Masaki Imai

Discloser Identifier: 922662

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1058929

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 922660

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 419009

Disclosure Purpose: 22-14302

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Daiichi Sankyo Company LTD	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Development of influenza vaccines <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> JP21fk0108615 <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> JP223fa627001 <i>Additional Information:</i> Grant to the institution for vaccine development		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> JP21wm0125002 <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> JP20nk0101632 <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		
Japan Agency for Medical Research and Development	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> JP21fk0108552 <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		
KM Biologics	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Development of novel influenza vaccines <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		
Kyoritsu Seiyaku	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Development of adjuvants <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		

Entity	Type	Interest Held By
Shionogi	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Evaluation of influenza drugs <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		
Toyama Chemical	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> Evaluation of influenza drugs <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		
US NIH	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> 75N93021C00014 <i>Additional Information:</i> The Center for Research on Influenza Pathogenesis and Transmission		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		
US NIH	Grant / Contract	Self
<i>Recipient Name:</i> Yoshihiro Kawaoka <i>Grant / Contract Description:</i> HHSN272201400008C <i>Additional Information:</i> The Center for Research on Influenza Pathogenesis		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - Influenza reverse genetics	-	Self
<i>Description:</i> Influenza reverse genetics <i>Patent Status:</i> Issued <i>Filing Jurisdiction:</i> <i>Licensees:</i>		
<i>Patent Number:</i> US 20160137987 A1 <i>Patent Holder:</i>		
Licensee	Title	Date
MedImmune, LLC		
<i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

Yes.

- a. Please list the other authors' names here.

Masaki Imai, D.V.M., Ph.D. Mutsumi Ito, D.V.M. Maki Kiso, D.V.M., Ph.D. Seiya Yamayoshi, D.V.M., Ph.D. Ryuta Uraki, Ph.D. Shuetsu Fukushi, Ph.D. Shinji Watanabe, D.V.M., Ph.D. Tadaki Suzuki, M.D., Ph.D. Ken Maeda, D.V.M., Ph.D. Yuko Sakai-

Tagawa, Ph.D. Kiyoko Iwatsuki-Horimoto, D.V.M., Ph.D. Peter J. Halfmann, Ph.D.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Maki Kiso

Discloser Identifier: 419015

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1087198

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 606450

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 922658

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1089529

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1058925

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 897986

Disclosure Purpose: 22-14302

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.